title: Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both.
abstract: Forty six patients with lymphoid malignancies receiving autologous transplants using three different sources of hematopoietic stem cells were compared for engraftment parameters. Thirteen patients (five with multiple myeloma, seven with non-Hodgkin's lymphoma and one with Hodgkin's lymphoma) received autologous marrow with post-transplant growth factors (group 1). During the same time interval, 14 patients (five with multiple myeloma, six with non-Hodgkin's lymphoma and three with Hodgkin's lymphoma) were transplanted with autologous marrow plus recombinant granulocyte colony-stimulating factor (rhG-CSF)-mobilized peripheral blood stem cells (PBSC) and post-transplant growth factors (group 2). Nineteen patients (seven with multiple myeloma and 12 with non-Hodgkin's lymphoma) received rhG-CSF mobilized PBSC and post-transplant growth factors (group 3). All PBSC were collected after G-CSF mobilization (16 micrograms/kg/day s.c. for 6 days) without prior chemotherapy. After high-dose myeloablative chemotherapy or chemoradiotherapy, the median days to recovery of neutrophils to levels of 0.5 and 1.0 x 10(9)/l were 12 vs. 9 vs. 9 days (P = 0.0003 (group 1 vs. group 2) and P = 0.53 (group 2 vs. group 3)) and 13 vs. 10 vs. 10 days (P = 0.0003 (group 1 vs. group 2) and 0.92 (group 2 vs. group 3)) for groups 1, 2 and 3, respectively. The median day to platelet transfusion independence was 22 vs. 11 vs. 11 days (P = 0.001 (group 1 vs. group 2) and P = 0.50 (group 2 vs. group 3)) for groups 1, 2 and 3, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, Washington 98104, USA.
authors.forename: I
authors.initials: I
authors.lastname: Langenmayer
authors.forename: C
authors.initials: C
authors.lastname: Weaver
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: K
authors.initials: K
authors.lastname: Lilleby
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: K
authors.initials: K
authors.lastname: Longin
authors.forename: S
authors.initials: S
authors.lastname: Rowley
authors.forename: R
authors.initials: R
authors.lastname: Storb
authors.forename: J
authors.initials: J
authors.lastname: Singer
authors.forename: W I
authors.initials: WI
authors.lastname: Bensinger
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006133:Growth Substances / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000601:surgery*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery*; D016019:Survival Analysis
chemical_list: D006133:Growth Substances